Award vesting grace period (in years) Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Grace Period Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Grace Period SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Statistical Measurement Statistical Measurement [Domain] Underwriters allotment option, term (in days) Sale Of Sock, Over-Allotment Option, Term Sale Of Sock, Over-Allotment Option, Term Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Line of credit, maximum borrowing capacity, number of available tranches Line Of Credit Facility, Maximum Borrowing Capacity, Number Of Available Tranches Line Of Credit Facility, Maximum Borrowing Capacity, Number Of Available Tranches Dilutive effect of common stock options and SARs Common Stock Options and Stock Appreciation Rights (SARS) [Member] Common Stock Options and Stock Appreciation Rights (SARS) Restricted cash Restricted Cash, Current Award Timing Predetermined Award Timing Predetermined [Flag] 2026 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Entity File Number Entity File Number Additional Paid-In Capital Additional Paid-in Capital [Member] Other Noncurrent Assets Other Noncurrent Assets [Member] Refund liability to customer, gross Contract with Customer, Refund Liability, Gross Contract with Customer, Refund Liability, Gross Tabular List, Table Tabular List [Table Text Block] Leases [Abstract] Schedule of Liability Related to Sale of Future Royalties Other Noncurrent Liabilities [Table Text Block] Upfront payment Asset Acquisition, Upfront Payment Asset Acquisition, Upfront Payment New Accounting Pronouncements - Recently Adopted/Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Accounts payable Increase (Decrease) in Accounts Payable Balance at Beginning of Period Balance at End of Period Contract asset Contract with Customer, Asset, after Allowance for Credit Loss, Current Interest expense Interest Income (Expense), Nonoperating Payments for royalties Payments for Royalties License License [Member] Share-Based Payment Arrangement, Tranche Three, Third Anniversary After Grant Date, Subjected To Individual Continued Service Share-Based Payment Arrangement, Tranche Three, Third Anniversary After Grant Date, Subjected To Individual Continued Service [Member] Share-Based Payment Arrangement, Tranche Three, Third Anniversary After Grant Date, Subjected To Individual Continued Service Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Term Loan Facility, Tranche B Term Loan Facility, Tranche B [Member] Term Loan Facility, Tranche B Basic (in dollars per share) Basic net income (loss) per share (in dollars per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Additions Contract With Customer Liability Additions Contract with customer liability additions. Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Common stock, reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance PRODUCT REVENUE AND PROVISIONS FOR VARIABLE CONSIDERATION Revenue from Contract with Customer [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Schedule of Segment Financial Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Restricted stock unit vesting (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Proceeds from sale of stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Area of property leased (in square feet) Area of Real Estate Property Transaction price Revenue, Remaining Performance Obligation, Amount Other Other Assets, Miscellaneous, Noncurrent Adjustment to Compensation, Amount Adjustment to Compensation Amount Less: unamortized discount and issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Principles of Consolidation Consolidation, Policy [Policy Text Block] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Share-based Payment Arrangement, Option Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Antidilutive Securities Antidilutive Securities [Axis] Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Insider Trading Policies and Procedures [Line Items] Stock-based compensation expense Total stock-based compensation Share-Based Payment Arrangement, Expense Common stock, authorized (in shares) Common stock, authorized (in shares) Common Stock, Shares Authorized Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Royalty payments Royalty Payments Due Royalty payments due. Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Current assets: Assets, Current [Abstract] Canceled and forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Total liabilities and stockholders' equity Liabilities and Equity Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Liabilities and stockholders' equity Liabilities and Equity [Abstract] Cover [Abstract] Cover [Abstract] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Maximum Maximum [Member] Options exercisable at end of period, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Accounting Policies [Abstract] Accounting Policies [Abstract] Termination of agreement eligible by counterparty, period after effective agreement date (in months) Contract With Customer, Termination Notice Period, Period After Effective Agreement Date Contract With Customer, Termination Notice Period, Period After Effective Agreement Date Schedule of Future Commitments under Non-Cancelable Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Lessee, operating lease, leased square feet Lessee, Operating Lease, Leased Square Feet Lessee, Operating Lease, Leased Square Feet Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Current operating lease liabilities Operating Lease, Liability Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company Tiered royalties (as percent) Revenue, Remaining Performance Obligation, Variable Consideration, Royalty Percentage Revenue, Remaining Performance Obligation, Variable Consideration, Royalty Percentage Other long-term liabilities Other Liabilities, Noncurrent Proceeds from the sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Statement of Financial Position Location, Activity, Accrual [Axis] Statement of Financial Position Location, Activity, Accrual [Axis] Proceeds from the issuance of debt Proceeds from Issuance of Debt Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Operating lease, remaining lease term (in years) Lessee, Operating Lease, Remaining Lease Term Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Current portion of long-term debt Long-Term Debt, Current Maturities Company Selected Measure Amount Company Selected Measure Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Line of Credit Facility [Table] Line of Credit Facility [Table] Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Employees Employees [Member] Employees Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Schedule of Prepaid Expenses and Other Current Assets Schedule of Other Current Assets [Table Text Block] Cyclerion Cyclerion [Member] Cyclerion Name Measure Name Letter of Credit Letter of Credit [Member] Schedule of Stock-Based Compensation Expense in Consolidated Statement of Operations and Comprehensive Loss Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Secured Debt Secured Debt [Member] Operating lease liabilities Operating Lease, Liability, Current Termination period, prior written notice (in days) Termination Period, Prior Written Notice Termination Period, Prior Written Notice Class of Stock [Line Items] Class of Stock [Line Items] Document Fiscal Period Focus Document Fiscal Period Focus Award Timing Method Award Timing Method [Text Block] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Award Type Award Type [Axis] Proceeds from customers Proceeds from Customers Long-term deferred revenue Contract with Customer, Liability, Noncurrent Total term loans Long-Term Debt Total assets Assets Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Percentage of net product margin on sales in collaborative arrangement Collaborative Arrangement, Rights And Obligations, Percentage Of Net Product Margin On Sales Collaborative Arrangement, Rights And Obligations, Percentage Of Net Product Margin On Sales Non-cash royalty revenue related to sale of future royalties Contractual Arrangement, Royalties Agreement, Noncash Royalty Revenue Contractual Arrangement, Royalties Agreement, Noncash Royalty Revenue Schedule of RSU and PSU Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Trading Symbol Trading Symbol Vested, weighted-average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Development milestone payment Asset Acquisition, Development Milestone Payment Asset Acquisition, Development Milestone Payment Geographical Geographical [Domain] Number of equal quarterly installments Share Based Compensation Arrangement By Share Based Payment Award Periodic Vesting Number Of Installments Share-based compensation arrangement by share-based payment award, periodic vesting, number of installments. Purchase commitment, option for non-auto renewal, prior written notice period (in months) Purchase Commitment, Option For Non-Auto Renewal, Prior Written Notice Period Purchase Commitment, Option For Non-Auto Renewal, Prior Written Notice Period Payments due to Q32 Accrued Milestone Payments Due, Current Accrued Milestone Payments Due, Current Public Stock Offering - Underwriting Agreement Public Stock Offering - Underwriting Agreement [Member] Public Stock Offering - Underwriting Agreement Entity Address, City or Town Entity Address, City or Town Operating Activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Liability related to sale of future royalties, net of current portion Long-term portion Contractual Arrangement, Royalties Agreement, Liability, Noncurrent Contractual Arrangement, Royalties Agreement, Liability, Noncurrent INVENTORIES Inventory Disclosure [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Maximum employee subscription amount Share-Based Compensation Arrangement By Share-based Payment Award, Maximum Employee Subscription Amount Share-Based Compensation Arrangement By Share-based Payment Award, Maximum Employee Subscription Amount Unvested RSUs Dilutive effect of RSUs Restricted Stock Units (RSUs) [Member] Income Statement Location Statement of Income Location, Balance [Domain] Total settlement royalties liability Contractual Arrangement, Royalties Agreement, Settlement Liability Contractual Arrangement, Royalties Agreement, Settlement Liability Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Non-cash interest expense Noncash Interest Expense Noncash interest expense. Entity Emerging Growth Company Entity Emerging Growth Company Dilutive effect of warrants Warrants Warrant [Member] Contract asset: Contract With Customer, Asset, After Allowance For Credit Loss, Current [Roll Forward] Contract With Customer, Asset, After Allowance For Credit Loss, Current Royalty payments Royalty Payment Royalty Payment Auryxia Drug Substance Auryxia Drug Substance [Member] Auryxia Drug Substance Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Number of options outstanding (in shares) Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Common stock, outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date [Member] Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date Provision for bad debts Accounts Receivable, Credit Loss Expense (Reversal) Change in fair value of warrant liability Change in fair value of warrant liability Fair Value Adjustment of Warrants Plan Name Plan Name [Axis] Restricted Stock Units (RSUs) And Performance Based Restricted Stock Units (PSUs) Restricted Stock Units (RSUs) And Performance Based Restricted Stock Units (PSUs) [Member] Restricted Stock Units (RSUs) And Performance Based Restricted Stock Units (PSUs) Tiered royalty payments, percentage Tiered Royalty Payments, Percentage Tiered Royalty Payments, Percentage PEO PEO [Member] Product revenue allowances excluding rebates Accrued Product Revenue Allowances Excluding Rebates, Current Accrued product revenue allowances current. Warrant purchased (in shares) Class of Warrant or Right, Warrants Purchased Class of Warrant or Right, Warrants Purchased Number of shares issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Operating lease, increase in rent, percentage Lessee, Operating Lease, Increase In Rent, Percentage Lessee, Operating Lease, Increase In Rent, Percentage Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Exercise of options Stock Issued During Period, Value, Stock Options Exercised License License Expense License expense. Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Accumulated Deficit Retained Earnings [Member] Prepaid expenses and other current assets Total prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Schedule of Components of Accrued Expenses and Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Cash, cash equivalents and restricted cash — beginning of period Cash, cash equivalents and restricted cash — end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Income Statement [Abstract] Income tax expense Income Tax Expense (Benefit) Basis spread on variable rate (as percent) Debt Instrument, Basis Spread on Variable Rate Sale of Stock Sale of Stock [Domain] Warrant liability Derivative Liability, Noncurrent Preferred stock, issued (in shares) Preferred Stock, Shares Issued Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Product and Service Product and Service [Domain] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] HealthCare Royalty Partners IV, L.P. HealthCare Royalty Partners IV, L.P. [Member] HealthCare Royalty Partners IV, L.P. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Additions Contract With Customer Asset Additions Contract with customer asset additions. Direct cost of product and other revenue Product and Other Revenue Expense Product and Other Revenue Expense Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Working Capital Fund liability, current portion Current portion Contract with Customer, Refund Liability, Current Proceeds from the exercise of stock options Proceeds from Stock Options Exercised City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities, Current Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number JT and Torii Japan Tobacco Incorporation And Torii Pharmaceutical Company Limited [Member] Japan tobacco incorporation and torii pharmaceutical company limited. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Exit fee percentage Debt Instrument, Exit Fee Percentage Debt Instrument, Exit Fee Percentage Development And Commercialize Collaboration Agreement Development And Commercialize Collaboration Agreement [Member] Development and commercialize collaboration agreement Proceeds from line of credit Proceeds from Long-Term Lines of Credit Schedule of Changes in Contract Assets and Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Fair value at grant date (in dollars per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Fair Value At Grant Date Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Fair Value At Grant Date Transaction fee percentage Debt Instrument, Transaction Fee Percentage Debt Instrument, Transaction Fee Percentage Investing Activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Unrecognized compensation costs, options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation SEC Schedule, 12-09, Valuation Allowances and Reserves SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Schedule of Assumptions Used in Black-Scholes Option Pricing Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Selling, general and administrative Selling, General and Administrative Expenses [Member] Cost of goods sold Cost of Sales [Member] Goodwill Goodwill Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Maximum annual royalty payout capacity Contractual Arrangement, Royalties Agreement, Maximum Annual Royalty Payout Capacity Contractual Arrangement, Royalties Agreement, Maximum Annual Royalty Payout Capacity PEO Total Compensation Amount PEO Total Compensation Amount Purchase Commitment, Excluding Long-term Commitment Purchase Commitment, Excluding Long-Term Commitment [Axis] Long-Term Debt, Type Long-Term Debt, Type [Axis] Depreciation Depreciation Earnings per share: Earnings Per Share, Basic and Diluted EPS [Abstract] Earnings Per Share, Basic and Diluted EPS LIABILITY RELATED TO SETTLEMENT ROYALTIES, WORKING CAPITAL FUND LIABILITY AND LIABILITY RELATED TO SALE OF FUTURE ROYALTIES Other Liabilities Disclosure [Text Block] Numerator Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Equity Components Equity Components [Axis] Royalty payments License Collaboration And Other Revenue, Royalties [Member] License Collaboration And Other Revenue, Royalties NATURE OF BUSINESS Nature of Operations [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Product revenue, net Product [Member] Number of reportable segments Number of Reportable Segments Contract with Customer, Basis of Pricing Contract with Customer, Basis of Pricing [Axis] Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Sublicense Agreement Sublicense Agreement [Member] Sublicense agreement. Warrant exercise period (in years) Warrants and Rights Outstanding, Term Goodwill, accumulated impairment losses Goodwill, Impaired, Accumulated Impairment Loss Other Performance Measure, Amount Other Performance Measure, Amount Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Inventory [Line Items] Inventory [Line Items] Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Payments of issuance costs related to BlackRock Credit Agreement Payments of Debt Issuance Costs Entity Address, State or Province Entity Address, State or Province Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total current liabilities Liabilities, Current Over-Allotment Option Over-Allotment Option [Member] Inventory [Axis] Inventory [Axis] Individual: Individual [Axis] Vesting Vesting [Axis] Restricted cash Restricted Cash Repayment of liability related to settlement royalties Repayment Of Liability Related To Settlement Royalties Repayment Of Liability Related To Settlement Royalties Other Other Assets, Current Research and Development Expense Research and development Research and Development Expense [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Net cash provided by (used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Milestone revenue Milestone Payment Received Milestone payment received. Inventories Inventories [Member] Document Fiscal Year Focus Document Fiscal Year Focus Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Sales to AG Distributor Sales to AG Distributor [Member] Sales to AG Distributor STOCK-BASED COMPENSATION PLANS Shareholders' Equity and Share-Based Payments [Text Block] Operating right-of-use assets Operating Lease, Right-of-Use Asset Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Entity Interactive Data Current Entity Interactive Data Current Operating lease, cost Operating Lease, Cost Plan Name Plan Name [Domain] Issuance of warrants in connection with BlackRock Credit Agreement Non-Cash Financing Activities, Issuance of Warrants Non-Cash Financing Activities, Issuance of Warrants Unrecognized compensation costs, options, period for recognition (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Exercise of options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Equity [Abstract] Equity [Abstract] Accrued manufacturing costs Accrued Manufacturing Costs, Current Accrued Manufacturing Costs, Current Exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Product rebates Accrued Product Rebates, Current Accrued Product Rebates, Current Schedule of Equity Incentive Plans Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Contract liability: Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expense Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Other long-term assets Total other long-term assets Other Assets, Noncurrent Royalties due to Panion & BF Biotech, Inc. Accrued Royalties, Current Entity Central Index Key Entity Central Index Key PEO Name PEO Name Schedule of Future Principal Payments on the Term Loans Schedule of Maturities of Long-Term Debt [Table Text Block] Aggregate net proceeds from offering Sale of Stock, Consideration Received on Transaction Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Office And Storage Space Office And Storage Space [Member] Office And Storage Space Development And Commercialize Research And License Agreement Development And Commercialize Research And License Agreement [Member] Development and commercialize research and license agreement. Arrangement Duration Trading Arrangement Duration Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Share Based Compensation Award Tranche One Share-Based Payment Arrangement, Tranche One [Member] STA Pharmaceutical Hong Kong Limited STA Pharmaceutical Hong Kong Limited [Member] STA Pharmaceutical Hong Kong Limited Late fee percentage Debt Instrument, Late Fee Percentage Debt Instrument, Late Fee Percentage Expected volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Current portion of deferred revenue Contract with Customer, Liability, Current Segments [Axis] Segments [Axis] Exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Work-in-process Inventory, Work in Process, Net of Reserves Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Inventory, Current [Table] Inventory, Current [Table] Regulatory Milestone Payments Regulatory Milestone Payments [Member] Regulatory milestone payments. Rebates, Fees and Other Deductions Rebates Fees And Other Deductions [Member] Rebates, Fees and other Deductions. Annual interest rate, increase (as percent) Debt Instrument, Annual Interest Rate, Increase (Decrease) Debt Instrument, Annual Interest Rate, Increase (Decrease) Assets Assets [Abstract] Additional payment term Asset Acquisition, Additional Payment Term Asset Acquisition, Additional Payment Term Long-term debt, net of current portion Long-Term Debt, Excluding Current Maturities Credit Facility Credit Facility [Axis] Inventories, long-term Long-term inventories Inventory, Noncurrent Underlying Security Market Price Change Underlying Security Market Price Change, Percent Share-Based Payment Arrangement, Tranche Two, Following First Anniversary After Grant Date Share-Based Payment Arrangement, Tranche Two, Following First Anniversary After Grant Date [Member] Share-Based Payment Arrangement, Tranche Two, Following First Anniversary After Grant Date Refund liability to customer, amortization of discount Contract with Customer, Refund Liability, Amortization of Discount Contract with Customer, Refund Liability, Amortization of Discount Balance Sheet Location Statement of Financial Position Location, Balance [Axis] Vesting Vesting [Domain] Adjustments related to prior year sales Valuation Allowances And Reserves Adjustments Related To Prior Period Sales Valuation allowances and reserves adjustments related to prior period sales. Debt Instrument Debt Instrument [Axis] Revenue, remaining performance obligation, profit share percentage Revenue, Remaining Performance Obligation, Variable Consideration, Profit Share Percentage Revenue, Remaining Performance Obligation, Variable Consideration, Profit Share Percentage Forfeited and canceled, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Vifor (International) Ltd. Vifor International Limited [Member] Vifor International Limited. FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Total security deposit in connection with lease Lessee, Operating Lease, Security Deposit Lessee, Operating Lease, Security Deposit Credit Facility Credit Facility [Domain] Stockholders' equity: Equity, Attributable to Parent [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Entity Address, Address Line One Entity Address, Address Line One Research and development Research and Development Expense Panion & BF Biotech, Inc Panion & BF Biotech, Inc [Member] Panion & BF Biotech, Inc Debt instrument, interest rate (as percent) Debt Instrument, Interest Rate, Stated Percentage Schedule of Product Revenues Revenue from External Customers by Products and Services [Table Text Block] Bad debt expense Accounts Receivable, Credit Loss Expense Accounts Receivable, Credit Loss Expense Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Variable rate, floor (as percent) Debt Instrument, Variable Rate Floor Debt Instrument, Variable Rate Floor Expiration period beginning with first commercial sale (in years) Expiration Period Beginning with First Commercial Sale Expiration Period Beginning with First Commercial Sale Supply agreement Supply Agreement [Member] Supply Agreement Panion royalty Royalty Expense Proceeds from issuance of common stock, net of issuance costs Proceeds From Issuance Of Common Stock Net Of Issuance Costs Proceeds from issuance of common stock net of issuance costs. Fair Value as of Grant Date Award Grant Date Fair Value Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss Entity Registrant Name Entity Registrant Name Other long-term assets Increase (Decrease) in Other Noncurrent Assets Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] CSL Vifor CSL Vifor [Member] CSL Vifor Dilutive effect (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Title of Individual Title and Position [Domain] Forfeited and canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unrecognized compensation costs, stock Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Deductions Contract With Customer Liability Deductions Contract with customer liability deductions. Inducement Award Program Inducement Award Program [Member] Inducement award program. Document Quarterly Report Document Quarterly Report Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Counterparty Name Counterparty Name [Domain] Number of operating segments Number of Operating Segments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Options outstanding, weighted-average remaining contractual life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Sale of stock, consideration received, gross Sale of Stock, Consideration Received on Transaction, Gross Sale of Stock, Consideration Received on Transaction, Gross SEC Schedule, 12-09, Valuation Allowances and Reserves Type SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Granted, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Warrants issued (in shares) Class of Warrant or Right, Warrants Issued Class of Warrant or Right, Warrants Issued Commercial milestone payment Asset Acquisition, Consideration Transferred, Contingent Consideration, Commercial Milestone Payment "Asset Acquisition, Consideration Transferred, Contingent Consideration, Commercial Milestone Payment Auryxia Auryxia [Member] Auryxia Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Number of performance obligations Number Of Performance Obligations Number of performance obligations. Non-PEO NEO Non-PEO NEO [Member] Options outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Accounts receivable Accounts Receivable [Member] Proceeds from sale of stock under    employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Interest expense Interest Expense, Debt Sale of Stock Sale of Stock [Axis] Name Trading Arrangement, Individual Name Award Type Award Type [Domain] Issuance and sale of equity securities Issuance And Sale Of Equity Securities, Amount Issuance And Sale Of Equity Securities, Amount Share-Based Payment Arrangement, Tranche Two, Second Anniversary After Grant Date, Subjected To Individual Continued Service Share-Based Payment Arrangement, Tranche Two, Second Anniversary After Grant Date, Subjected To Individual Continued Service [Member] Share-Based Payment Arrangement, Tranche Two, Second Anniversary After Grant Date, Subjected To Individual Continued Service Contract with Customer, Basis of Pricing Contract with Customer, Basis of Pricing [Domain] Lessee, operating lease, expiration period (in months) Lessee, Operating Lease, Expiration Period Lessee, Operating Lease, Expiration Period Equity Awards Adjustments Equity Awards Adjustments [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Excess firm purchase commitment charge Long-Term Purchase Commitment, Amount Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Debt Instrument, Name Debt Instrument, Name [Domain] Schedule of Product Revenue Allowance and Provision Categories Schedule Of Product Revenue Allowance And Reserve Categories [Table Text Block] Schedule Of Product Revenue Allowance And Reserve Categories. Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Non-cash operating lease expense Straight Line Rent Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Deferred revenue — beginning of the period Revenue recognized Contract with Customer, Liability, Revenue Recognized Current provisions related to sales in current year SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Schedule of Allowance for Credit Losses Accounts Receivable, Allowance for Credit Loss [Table Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Asset acquisition, consideration transferred, transaction cost Asset Acquisition, Consideration Transferred, Transaction Cost Outstanding beginning balance, weighted average grant date fair value (in dollars per share) Outstanding ending balance, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Prepayment fee percentage Debt Instrument, Prepayment Fee Percentage Debt Instrument, Prepayment Fee Percentage Denominator Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Dilutive effect of ESPP Employee Stock [Member] Contract cost incurred in research and development activities Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross Maximum aggregate royalty payout capacity Contractual Arrangement, Royalties Agreement, Maximum Aggregate Royalty Payout Capacity Contractual Arrangement, Royalties Agreement, Maximum Aggregate Royalty Payout Capacity Revenues Revenues [Abstract] Maximum number of shares per employee in any offering period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee Inventory [Domain] Inventory [Domain] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Debt covenant, revenue Debt Instrument, Covenant, Revenue Debt Instrument, Covenant, Revenue Net income (loss) per share: Earnings Per Share, Basic And Diluted1 [Abstract] Earnings Per Share, Basic And Diluted1 Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Term Loan Facility, Tranche A Term Loan Facility, Tranche A [Member] Term Loan Facility, Tranche A Total inventories Inventory Net Current And Non Current Inventory net current and non current. 2027 Long-Term Debt, Maturity, Year One Medice MEDICE Arzneimittel Pütter GmbH & Co. KG MEDICE Arzneimittel Pütter GmbH & Co. KG [Member] MEDICE Arzneimittel Pütter GmbH & Co. KG Segments [Domain] Segments [Domain] Deferred revenue Deferred Revenue [Member] Deferred revenue. Income Statement Location Statement of Income Location, Balance [Axis] Liability related to sale of future royalties, current portion Current portion (included in accrued expenses and other current liabilities) Contractual Arrangement, Royalties Agreement, Liability, Current Contractual Arrangement, Royalties Agreement, Liability, Current Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Balance Sheet Location Statement of Financial Position Location, Balance [Domain] Inventory Increase (Decrease) in Inventories Awards outstanding (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Outstanding, Number Share-Based Compensation Arrangement By Share-Based Payment Award, Outstanding, Number Inventories Inventories, current Inventory, Net Outstanding common stock options Share-Based Payment Arrangement, Option And Stock Appreciation Rights [Member] Share-Based Payment Arrangement, Option And Stock Appreciation Rights Warrant to purchase common stock (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Minimum Minimum [Member] Total security deposit in connection with lease Security Deposit Accumulated Other Comprehensive Income AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Schedule of Revenue Recognized Resulting from Changes in Contract Assets and Contract Liabilities Schedule Of Revenue Recognized Resulting From Changes In Contract Asset And Contract Liability [Table Text Block] Schedule of revenue recognized resulting from changes in contract asset and contract liability. Cost of goods sold Cost of Revenue [Abstract] Company Selected Measure Name Company Selected Measure Name Working Capital Fund liability, net of current portion Long-term portion Contract with Customer, Refund Liability, Noncurrent 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. INDEBTEDNESS Debt Disclosure [Text Block] Preferred stock $0.00001 par value; 25,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025 Preferred Stock, Value, Issued Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Purchase Commitment, Excluding Long-term Commitment Purchase Commitment, Excluding Long-Term Commitment [Domain] Accounts payable Payables Accounts Payable, Current Royalty true-up payments Royalty True-Up Payments Royalty True-Up Payments Purchase of IPR&D asset included in accrued expenses and other current liabilities In Process Research And Development Asset Expenditure Incurred But Not Yet Paid In Process Research And Development Asset Expenditure Incurred But Not Yet Paid Operating lease, payments Operating Lease, Payments Clinical trial costs Accrued Clinical Expenses Current Accrued clinical expenses current. Proceeds from issuance of stock under employee stock purchase plan Proceeds from Stock Plans SARs Stock Appreciation Rights (SARs) [Member] All Executive Categories All Executive Categories [Member] Finished goods Inventory, Finished Goods, Net of Reserves Common stock $0.00001 par value; 350,000,000 shares authorized at March 31, 2026 and December 31, 2025; 267,898,415 and 265,424,818 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively Common Stock, Value, Issued Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Share Based Compensation Award Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Operating lease extensions (in extension options) Lessee, Operating Lease, Renewal Options Lessee, Operating Lease, Renewal Options Title of Individual Title and Position [Axis] Diluted (in shares) Denominator for diluted net income (loss) per share - weighted average outstanding shares of common stock and assumed conversions (in shares) Weighted Average Number of Shares Outstanding, Diluted Commitments and contingencies (Note 10) Commitments and Contingencies Purchase commitment, option to extend, prior notice period (in months) Long-Term Purchase Commitment, Option To Extend, Prior Notice Period Long-Term Purchase Commitment, Option To Extend, Prior Notice Period Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date, Subjected To Individual Continued Service Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date, Subjected To Individual Continued Service [Member] Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date, Subjected To Individual Continued Service Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Amended Supply Agreement Amended Supply Agreement [Member] Amended Supply Agreement Additional upfront payment Asset Acquisition, Additional Upfront Payment Asset Acquisition, Additional Upfront Payment Entity Small Business Entity Small Business Refund liability to customer, amortization of deferred gain Contract with Customer, Refund Liability, Amortization of Deferred Gain Contract with Customer, Refund Liability, Amortization of Deferred Gain Preferred stock, outstanding (in shares) Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Tiered royalty payments as a percentage of net sales Tiered Royalty Payments as a Percentage of Net Sales Tiered Royalty Payments as a Percentage of Net Sales Document Transition Report Document Transition Report Underlying Securities Award Underlying Securities Amount Equity Component Equity Component [Domain] Liability related to settlement royalties, net of current portion Long-term portion Contractual Arrangement, Royalties Agreement, Settlement Liability, Noncurrent Contractual Arrangement, Royalties Agreement, Settlement Liability, Noncurrent Document Period End Date Document Period End Date PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Allowance for credit loss Beginning balance Ending balance Accounts Receivable, Allowance for Credit Loss Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Chargebacks and Discounts Chargebacks And Discounts [Member] Chargebacks and Discounts. Scenario Scenario [Axis] Options exercisable at end of period, weighted-average remaining contractual life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Operating lease liabilities Increase (Decrease) in Operating Lease Liability Share-based Compensation Award, Tranche, First Anniversary of Grant Date Share Based Compensation Award Tranche First Anniversary Of Grant Date [Member] Share-based compensation award, tranche, first anniversary of grant date. Document Type Document Type Unregistered stock held by customer (in shares) Contract With Customer, Number Of Unregistered Stock Held By Customer Contract With Customer, Number Of Unregistered Stock Held By Customer Level 3 Fair Value, Inputs, Level 3 [Member] NET INCOME (LOSS) PER SHARE Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Product and Service Product and Service [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Proceeds from common stock sold Proceeds from Issuance of Common Stock Settlement royalties liability, current portion Current portion (included in accrued expenses and other current liabilities) Contractual Arrangement, Royalties Agreement, Settlement Liability, Current Contractual Arrangement, Royalties Agreement, Settlement Liability, Current Long-term purchase commitment, option to terminate, prior notice period (at least) Long-Term Purchase Commitment, Option To Terminate, Prior Notice Period Long-Term Purchase Commitment, Option To Terminate, Prior Notice Period Total revenues Recognized revenue Revenue from Contract with Customer, Excluding Assessed Tax Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Number of financial institutions maintaining cash Cash, Number Of Financial Institutions Held Within Cash, Number Of Financial Institutions Held Within All Individuals All Individuals [Member] Upfront cash payment received Upfront Cash Payment Received Upfront cash payment received. Long-Term Debt, Type Long-Term Debt, Type [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Purchases of equipment Payments to Acquire Property, Plant, and Equipment Upfront payments Asset Acquisition, Consideration Transferred Name Forgone Recovery, Individual Name Expiration period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Total current assets Assets, Current Statistical Measurement Statistical Measurement [Axis] Repayment of WCF liability Repayment Of Working Capital Fund Liability Repayment Of Working Capital Fund Liability Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Other Liabilities Disclosure [Abstract] Akebia Therapeutics, Inc. 2023 Stock Incentive Plan (the 2023 Plan) (replaces 2014 Plan) Akebia Therapeutics, Inc. 2023 Stock Incentive Plan (the 2023 Plan) (replaces 2014 Plan), as amended 2023 Stock Incentive Plan Stock Incentive Plan, 2023 [Member] Stock Incentive Plan, 2023 Number of commercial products Number Of Commercial Products Number Of Commercial Products Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Purchase price at the end of offering period Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Refund liability to customer, interest rate (as percent) Contract with Customer, Refund Liability, Interest Rate Contract with Customer, Refund Liability, Interest Rate Private Placement Private Placement [Member] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Contingent consideration Asset Acquisition, Consideration Transferred, Contingent Consideration Keryx Equity Plans Keryx Equity Plans [Member] Keryx Equity Plans Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Total Working Capital Fund liability Contract with Customer, Refund Liability Current liabilities: Liabilities, Current [Abstract] Weighted-Average Contractual Life (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Geographical Geographical [Axis] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Vifor International Limited, First Investment Vifor International Limited, First Investment [Member] Vifor International Limited, First Investment Total operating expenses Operating Expenses Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Product Returns Returns [Member] Returns. Level 1 Fair Value, Inputs, Level 1 [Member] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Q32 Q32 [Member] Q32 SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Accrued expense and other current liabilities Increase (Decrease) in Accrued Liabilities Diluted (in dollars per share) Diluted net income (loss) per share (in dollars per share) Earnings Per Share, Diluted Forecast Forecast [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Title of 12(b) Security Title of 12(b) Security Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Non-cash financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Offering period (in months) Share Based Compensation Arrangement By Share Based Payment Award Offering Period Share-based compensation arrangement by share-based payment award, offering period. Number of shares sold in offering (in shares) Sale of Stock, Number of Shares Issued in Transaction Earnings Per Share [Abstract] Earnings Per Share [Abstract] Cost of purchased minimum quantity product Cost Of Purchased Minimum Quantity Product Cost of purchased minimum quantity product. Lessee, operating lease, cost of additional square foot (in dollars per sq foot) Lessee, Operating Lease, Cost Of Additional Square Foot Lessee, Operating Lease, Cost Of Additional Square Foot Debt instrument, cap rate (as percent) Debt Instrument, Interest Rate Cap Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Akebia Therapeutics, Inc. 2014 Incentive Plan, as amended (the 2014 Plan) 2014 Stock Incentive Plan Incentive Plan, 2014 [Member] Incentive Plan, 2014 Deferred revenue Increase (Decrease) in Contract with Customer, Liability ADDITIONAL BALANCE SHEET DETAIL Accounts Payable and Accrued Liabilities Disclosure [Text Block] Less: present value adjustment Lessee, Operating Lease, Liability, Undiscounted Excess Amount Leased area subject to expiration Lessee, Operating Lease, Area Subject To Expiration Lessee, Operating Lease, Area Subject To Expiration Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cyclerion Amendment Cyclerion Amendment [Member] Cyclerion Amendment Laboratory Space Laboratory Space [Member] Laboratory Space Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Award Timing Disclosures [Line Items] Schedule of Components Inventory Schedule of Inventory, Current [Table Text Block] Total before unamortized discount and issuance costs Long-Term Debt, Gross Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Compensation and related benefits Employee-related Liabilities, Current Total lease commitments Lessee, Operating Lease, Liability, to be Paid Lease extension period Lessee, Operating Lease, Renewal Term Charge for purchase of IPR&D asset Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff CAPITAL STOCK Equity [Text Block] Specified development and regulatory milestone payments, contingent on a product-by-product basis Asset Acquisition, Consideration Transferred, Contingent Consideration, Development and Regulatory Milestone Payments Asset Acquisition, Consideration Transferred, Contingent Consideration, Development and Regulatory Milestone Payments Product return provisions, current portion Accrued Product Revenue Return Reserves, Current Accrued Product Revenue Return Reserves, Current License, collaboration and other revenue License Collaboration And Other Revenue [Member] License, collaboration and other revenue. Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Expiration Date Trading Arrangement Expiration Date Schedule of Revenues Recognized from License, Collaboration and Other Significant Agreements Collaborative Arrangement Revenue Recognition [Table Text Block] Collaborative arrangement revenue recognition. Other Other Accrued Liabilities, Current Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Credits/payments made SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Property and equipment, net Property, Plant and Equipment, Net Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Adoption Date Trading Arrangement Adoption Date WuXi STA WuXi STA [Member] WuXi STA Unrecorded unconditional purchase obligation Unrecorded Unconditional Purchase Obligation, to be Paid, Year One Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Contract asset Contract with Customer, Asset, after Allowance for Credit Loss Entity Current Reporting Status Entity Current Reporting Status Supply Agreement, Patheon Inc. Supply Agreement, Patheon Inc. [Member] Supply Agreement, Patheon Inc. Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Eligible milestone payments (up to) Revenue, Remaining Performance Obligation, Variable Consideration Amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Total liability related to sale of future royalties Contractual Arrangement, Royalties Agreement, Liability Contractual Arrangement, Royalties Agreement, Liability Income (loss) from operations Operating Income (Loss) Line of Credit Line of Credit [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Gain on the sale of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Repayment of term debt Repayments of Debt Current Fiscal Year End Date Current Fiscal Year End Date Mitsubishi Tanabe Pharma Corporation Supply Agreement Mitsubishi Tanabe Pharma Corporation Supply Agreement [Member] Mitsubishi Tanabe Pharma Corporation Supply Agreement Weighted average shares of common stock outstanding: Weighted Average Number Of Shares Outstanding, Basic And Diluted [Abstract] Weighted Average Number Of Shares Outstanding, Basic And Diluted Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Tiered royalties, expected timing of satisfaction period (in years) Revenue, Remaining Performance Obligation, Variable Consideration, Royalty, Expected Timing Of Satisfaction, Period Revenue, Remaining Performance Obligation, Variable Consideration, Royalty, Expected Timing Of Satisfaction, Period Office Space Office Space [Member] Office space . Payables and Accruals [Abstract] Payables and Accruals [Abstract] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Additional awards available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Other income Other Nonoperating Income (Expense) Statement [Table] Statement [Table] Warrant liability Derivative Liability Maximum employee subscription rate (as percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Adjustments to reconcile net income (loss) to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] LICENSE, COLLABORATION AND OTHER REVENUE Collaborative Arrangement Disclosure [Text Block] Financing Activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Deferred revenue Balance at Beginning of Period Balance at End of Period Contract with Customer, Liability Term Loan Facility, Tranche C Term Loan Facility, Tranche C [Member] Term Loan Facility, Tranche C Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount All Adjustments to Compensation All Adjustments to Compensation [Member] Deductions Contract With Customer Asset Deductions Contract with customer asset deductions. Amendment Flag Amendment Flag Sale of stock, price per share (in dollars per share) Sale of Stock, Price Per Share 2028 Long-Term Debt, Maturity, Year Two LEASES Lessee, Operating Leases [Text Block] Termination Date Trading Arrangement Termination Date Net cash provided by (used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Measure: Measure [Axis] Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Debt covenant, revenue period (in months) Debt Instrument, Covenant, Revenue, Period Debt Instrument, Covenant, Revenue, Period Raw materials Inventory, Raw Materials, Net of Reserves Operating lease, incremental borrowing rates based on remaining lease term (in percent) Operating Lease, Weighted Average Discount Rate, Percent Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Term Loan Facility Term Loan Facility [Member] Term Loan Facility Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Schedule of Assets Measured or Disclosed at Fair Value on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Basic (in shares) Denominator for basic net income (loss) per share - weighted average outstanding shares of common stock (in shares) Weighted Average Number of Shares Outstanding, Basic Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Write-down of inventory Inventory Write-down Cost of product and other revenue Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Statement of Financial Position Location, Activity, Accrual [Domain] Statement of Financial Position Location, Activity, Accrual [Domain] Revenue Recognized in the Period: Change in Contract with Customer, Liability [Abstract] Options exercisable at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Termination of agreement by counterparty, written notice period (in months) Contract With Customer, Termination Notice Period Contract With Customer, Termination Notice Period Subsequent Events [Abstract] Segment Reporting [Abstract] Debt covenant, cash and cash equivalents Debt Instrument, Covenant, Cash And Cash Equivalents Debt Instrument, Covenant, Cash And Cash Equivalents Total cost of goods sold Cost of Revenue Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Other income (expense) Nonoperating Income (Expense) [Abstract] Entity Tax Identification Number Entity Tax Identification Number Less: Costs and Expenses [Abstract] Scenario Scenario [Domain] At-The-Market Sale Agreement, Authorized April 2022, Amended At-The-Market Sale Agreement, Authorized April 2022, Amended [Member] At-The-Market Sale Agreement, Authorized April 2022, Amended Asset Acquisition [Axis] Asset Acquisition [Axis] Siegfried Evionnaz SA Siegfried Evionnaz S A [Member] Siegfried Evionnaz SA. Outstanding beginning balance (in dollars per share) Outstanding ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Vafseo Vafseo [Member] Vafseo Common stock, issued (in shares) Common Stock, Shares, Issued Cost of research services Cost Of Research Services Cost of research services. Effect of potential dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] License Collaboration And Other Revenue [Abstract] License Collaboration And Other Revenue [Abstract] License, collaboration and other revenue. Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross GOODWILL Goodwill and Intangible Assets Disclosure [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Vifor International Limited, Second Investment Vifor International Limited, Second Investment [Member] Vifor International Limited, Second Investment Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Schedule of Other Long-Term Assets Schedule of Other Assets, Noncurrent [Table Text Block] SUBSEQUENT EVENTS Subsequent Events [Text Block] Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name Canceled and forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price License Agreement License Agreement [Member] License agreement. Q32 Asset Purchase Agreement Q32 Asset Purchase Agreement [Member] Q32 Asset Purchase Agreement Percentage of royalty payment to be received once maximum annual royalty payout has been paid Contractual Arrangement, Royalties Agreement, Percentage Contractual Arrangement, Royalties Agreement, Percentage 2026 Long-Term Debt, Maturity, Remainder of Fiscal Year Cambridge Cambridge [Member] Cambridge. Total liabilities Liabilities Antidilutive Securities, Name Antidilutive Securities, Name [Domain] TPC Tanabe Pharma Corporation Tanabe Pharma Corporation [Member] Mitsubishi Tanabe Pharma Corporation. Line of credit, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Minimum purchase commitment Purchase Commitment, Remaining Minimum Amount Committed Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Annual effective interest rate (as percent) Contractual Arrangement, Royalties Agreement, Interest Rate, Effective Percentage Contractual Arrangement, Royalties Agreement, Interest Rate, Effective Percentage Operating expenses: Operating Expenses [Abstract] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Public Stock Offering Public Stock Offering [Member] Public Stock Offering Reportable Segment Reportable Segment [Member] Reportable Segment Issuance of common stock, net of    issuance costs Stock Issued During Period, Value, New Issues Statement [Line Items] Statement [Line Items] Acquired Licenses Acquired Licenses [Member] Acquired Licenses Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Counterparty Name Counterparty Name [Axis] Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Common Stock Common Stock [Member] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Professional fees Accrued Professional Fees, Current Secured Overnight Financing Rate (SOFR) [Member]